智通财经APP获悉，阿斯利康公司(AZN.US)今日宣布，其重磅免疫疗法Imfinzi(durvalumab)已获得欧洲药品管理局(EMA)人用药品委员会(CHMP)积极意见，推荐在欧盟(EU)获批作为单药，用于治疗接受铂类放化疗(CRT)后病情未进展的成人局限期小细胞肺癌(LS-SCLC)。
这一推荐是基于发表在《新英格兰医学杂志》上的3期临床试验ADRIATIC的结果。
小细胞肺癌(SCLC)是一种高度侵袭性的肺癌。局限期小细胞肺癌即使在标准化疗和放疗初步应答良好后，通常也会迅速复发和进展。LS-SCLC的预后尤为不良，仅有15%–30%的患者在确诊五年后仍存活。
荷兰阿姆斯特丹大学医学中心临床试验放疗教授，ADRIATIC试验主要研究员Suresh Senan博士表示：“ADRIATIC是几十年来首个在局限期小细胞肺癌中显示出生存获益的3期试验，接受Imfinzi治疗的患者死亡风险降低了27%。”
Imfinzi是一种人源化的单克隆抗体。通过与PD-L1的结合，阻断PD-L1与PD-1和CD80蛋白的结合，进而抑制肿瘤的免疫逃逸机制。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.